Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia
Nowadays, the development of factor VIII and IX inhibitors in patients with hemophilia is considered as the most challenging in the treatment of hemophilia. Immune tolerance induction (ITI) therapy is an approach for eradication of inhibitors. Some ITI protocols are routinely in use for the eradicat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-06-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/1076029620913951 |
| _version_ | 1818068338243272704 |
|---|---|
| author | Zahra Rezaieyazdi MD Hassan Mansouritorghabeh PhD |
| author_facet | Zahra Rezaieyazdi MD Hassan Mansouritorghabeh PhD |
| author_sort | Zahra Rezaieyazdi MD |
| collection | DOAJ |
| description | Nowadays, the development of factor VIII and IX inhibitors in patients with hemophilia is considered as the most challenging in the treatment of hemophilia. Immune tolerance induction (ITI) therapy is an approach for eradication of inhibitors. Some ITI protocols are routinely in use for the eradication of inhibitors in patients with hemophilia. Moreover, such a therapeutic regimen may facilitate the tendency to reduced bone density in patients with inhibitor. This study scheduled to investigate whether that predisposing role of ITI protocols with an immunosuppressive agent has considered or not. By a literature review, published ITI protocols in hemophilia with inhibitors were evaluated. Among them, 51 papers found and studied thoroughly. None of them had performed the bone mineral examination in patients with hemophilia and inhibitor under treatment. Since there are 2 coexisting facilitating factors in these protocols, considering the bone mineral density study for patients with inhibitor who are undergoing ITI protocols with an immunosuppressive agent is recommended. |
| first_indexed | 2024-12-10T15:37:59Z |
| format | Article |
| id | doaj.art-90c6756b8152409498cc3fecb3616c31 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-12-10T15:37:59Z |
| publishDate | 2020-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-90c6756b8152409498cc3fecb3616c312022-12-22T01:43:11ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232020-06-012610.1177/1076029620913951Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in HemophiliaZahra Rezaieyazdi MD0Hassan Mansouritorghabeh PhD1 Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, IranNowadays, the development of factor VIII and IX inhibitors in patients with hemophilia is considered as the most challenging in the treatment of hemophilia. Immune tolerance induction (ITI) therapy is an approach for eradication of inhibitors. Some ITI protocols are routinely in use for the eradication of inhibitors in patients with hemophilia. Moreover, such a therapeutic regimen may facilitate the tendency to reduced bone density in patients with inhibitor. This study scheduled to investigate whether that predisposing role of ITI protocols with an immunosuppressive agent has considered or not. By a literature review, published ITI protocols in hemophilia with inhibitors were evaluated. Among them, 51 papers found and studied thoroughly. None of them had performed the bone mineral examination in patients with hemophilia and inhibitor under treatment. Since there are 2 coexisting facilitating factors in these protocols, considering the bone mineral density study for patients with inhibitor who are undergoing ITI protocols with an immunosuppressive agent is recommended.https://doi.org/10.1177/1076029620913951 |
| spellingShingle | Zahra Rezaieyazdi MD Hassan Mansouritorghabeh PhD Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia Clinical and Applied Thrombosis/Hemostasis |
| title | Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia |
| title_full | Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia |
| title_fullStr | Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia |
| title_full_unstemmed | Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia |
| title_short | Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia |
| title_sort | clinical care of bone health in patients on the immune tolerance induction s protocols with an immunosuppressive agent for inhibitor eradication in hemophilia |
| url | https://doi.org/10.1177/1076029620913951 |
| work_keys_str_mv | AT zahrarezaieyazdimd clinicalcareofbonehealthinpatientsontheimmunetoleranceinductionsprotocolswithanimmunosuppressiveagentforinhibitoreradicationinhemophilia AT hassanmansouritorghabehphd clinicalcareofbonehealthinpatientsontheimmunetoleranceinductionsprotocolswithanimmunosuppressiveagentforinhibitoreradicationinhemophilia |